On 25 June 2026, Bella Hadid posted a series of tearful Instagram stories describing a debilitating Lyme disease flare-up that left her breathless walking to the kitchen and unable to find relief despite following multiple medical protocols. The posts, which she later apologised for as potentially startling, triggered an outpouring of support from her 59 million followers and renewed public attention on the long-term toll of the tick-borne bacterial infection.

Lyme disease, caused by the bacterium Borrelia and transmitted through the bite of infected black-legged ticks, can produce a range of symptoms including extreme fatigue, joint pain, cognitive difficulties known as “brain fog,” and, in prolonged cases, severe depression and isolation. The US Centers for Disease Control and Prevention notes that early diagnosis and antibiotic treatment are effective, but delayed recognition can lead to persistent symptoms. Hadid, diagnosed in 2013 at age 16, described the cyclical nature of the illness: periods of relative stability followed by relapses that render previous treatments ineffective, a pattern familiar to many chronic Lyme patients.

Hadid’s candour resonated far beyond her US base. Indonesian, German, Spanish and Arabic-language outlets amplified her account, often pairing it with medical explainers. In Cairo, Egyptian actress Heba Magdy separately posted a photo of her swollen, makeup-free face, telling followers she was enduring “the most difficult illness and the most difficult treatment” without disclosing a diagnosis, prompting a wave of supportive messages from fellow artists. In Lagos, Nollywood star Ini Dima-Okojie revealed she had carried her baby while navigating multiple fibroids, describing moments that “stretched me physically, mentally, and emotionally.” Viewed together, these disclosures from different entertainment industries suggest a shift in how public figures in multiple regions use social media to demystify chronic and invisible illnesses.

Hadid has pledged to continue sharing her journey, and her posts have already driven traffic to public health resources on Lyme disease. The next factual milestone to watch is whether this heightened visibility translates into increased funding for research on post-treatment Lyme disease syndrome, a condition still debated in medical circles. No new clinical data or policy announcements have accompanied the current wave of attention.